Barcelona Institute for Global Health (ISGlobal) 266d ago

Presented by The Global Think-tank on Steatotic Liver Disease and recorded live in Barcelona on 6 June 2025, this engaging roundtable brings together leading global experts to address the under-recognized public health threat of MASLD/MASH. This webinar was done in collaboration with EU-funded project LIVERAIM. With 2025 marking the UN High-level meeting on Non-Communicable Diseases, there is a clear need for effective policies and regulatory frameworks. Recognizing chronic liver disease, especially due to MASLD/MASH, as one of the major non-communicable diseases would be a great starting point! This webinar offers valuable insights into the current and future priorities of liver health policy and regulation. Key Topics: ✅ Strategic pathways for MASLD/MASH to be included in global policy discussions ✅ Accelerating access to new treatments, reimbursements, and approvals ✅ The crucial role of payors in enabling early screening and linkage to care ✅ Navigating the complex regulatory landscape of drug and diagnostic approvals Who should watch? Clinicians involved in hepatology; health policy experts, regulatory experts, academics and researchers, industry, patient associations, patient advocates, primary healthcare professionals, gastroenterologists, hepatologists, and anyone interested in learning more about chronic liver disease from a policy perspective Moderators: 🔸Veronica Miller, PhD, Adjunct Professor IDV, Berkeley School of Public Health / Director, Forum for Collaborative Research, USA 🔸Jeffrey V. Lazarus, Professor, the Barcelona Institute for Global Health (ISGlobal), Spain and CUNY Graduate School of Public Health and Health Policy, NY, USA / Director, Global Think-tank on Steatotic Liver Disease Panelists: 🔸Keri Hildick, Chief Strategy Officer, Perspectum, UK 🔸Morten Karsdal, CEO, Nordic Bioscience, Denmark 🔸Luis Antonio Diaz Piga, Hepatologist/Researcher, MASLD Research Center, University of California San Diego, USA 🔸Gail Hinkson, CEO, Summit Clinical Research, LLC, USA